Primary care docs more willing to prescribe Exubera
Primary care physicians are more willing than endocrinologists to prescribe Exubera (insulin recombinant human, Pfizer), and half of managed care pharmacy directors indicated they will not cover the inhaled insulin on their formulary on the basis of improved compliance alone.
Primary care physicians are more willing than endocrinologists to prescribe Exubera (insulin recombinant human, Pfizer), and half of managed care pharmacy directors indicated they will not cover the inhaled insulin on their formulary on the basis of improved compliance alone, according to a report from Decision Resources. The Physician & Payer Forum report, entitled Reimbursement of Inhaled Insulins: Safety and Efficacy Concerns vs. Improved Patient Compliance, revealed that 54% of PCPs and 41% of endocrinologists said they would increase the number of prescriptions they write for insulin generally. The report also found that half of managed care organizations' pharmacy directors believe that inhaled insulin will promote earlier use of insulin among patients. Most do not perceive that inhaled insulin is worth a premium price over injectable insulin analogs, said the report.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
